- Real world evidence demonstrates pharmaceutical support
programs positively impact patient persistence with clozapine
treatment
- Study highlights significant differences
in clozapine persistence rates across pharmaceutical support
programs
DORVAL,
QC, May 28, 2024 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSX: HLS), a pharmaceutical company
focused on addressing unmet needs in the treatment of psychiatric
disorders and cardiovascular disease, announces that results from a
Quebec-based retrospective study
examining the positive impact of pharmaceutical support programs
("PSPs") on persistence with clozapine treatment have been
published in the Journal of Clinical Pharmacology and
Therapeutics.
The publication, titled "The Impact of Pharmaceutical Support
Programs on Persistence: Clinical, Human and Economic Impact of
Clozapine Support Programs in Quebec,
Canada", is based on an 18-month persistence study
conducted using data from the Régie de l' Assurance Maladie du
Québec ("RAMQ") for patients who were initiated on clozapine
treatment.
Clozapine PSPs were created to provide additional services to
help health care providers manage patients being treated with
clozapine which is the only approved treatment for
Treatment-Resistant Schizophrenia ("TRS") in Canada. Approximately 25-30% of people with
Schizophrenia have TRS. HLS's branded version of clozapine is
CLOZARIL® and its associated PSP is the CLOZARIL Support and
Assistance Network, or CSAN®.
The study highlights that helping patients maintain persistence
with clozapine treatment is a critical success factor for the
management of TRS patients, resulting in reduced pain and suffering
of the patient, improved treatment benefits, and reduced health
care costs. The study found that persistence rates were better when
clozapine was paired with a PSP, including a 69% reported
persistence rate overall for CSAN, as opposed to a 25% persistence
rate without a program. The study also notes that differences in
the offerings between PSPs can have an impact on persistence,
placing varying demands on the health care system.
"Improved persistence with clozapine treatment not only benefits
patients and their families, but it also saves the healthcare
system important resources, as patients who are stabilized on
clozapine treatment require fewer hospitalizations, emergency room
consultations and physician visits," said Jason A. Gross, Pharm.D., Vice President,
Scientific Affairs at HLS. "I'm very proud of the hard work
our CSAN team does every day on behalf of patients and
practitioners. This publication demonstrates the important impact
they have on patient care."
Link to
study:
https://www.medtextpublications.com/open-access/the-impact-of-pharmaceutical-support-programs-on-persistence-clinical-human-1641.pdf
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the
acquisition and commercialization of late-stage development,
commercial stage promoted and established branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting the central nervous system and cardiovascular therapeutic
areas. HLS's management team is composed of seasoned pharmaceutical
executives with a strong track record of success in these
therapeutic areas and at managing products in each of these
lifecycle stages. For more information visit:
www.hlstherapeutics.com
FORWARD LOOKING INFORMATION
This release includes forward-looking statements regarding
HLS and its business. Such statements are based on the current
expectations and views of future events of HLS's management. In
some cases the forward-looking statements can be identified by
words or phrases such as "may", "will", "expect", "plan",
"anticipate", "intend", "potential", "estimate", "believe" or the
negative of these terms, or other similar expressions intended to
identify forward-looking statements, including, among others,
statements with respect to HLS's pursuit of additional product and
pipeline opportunities in certain therapeutic markets, statements
regarding growth opportunities, expectations regarding financial
performance, and the NCIB and ASPP. The forward-looking events and
circumstances discussed in this release may not occur and could
differ materially as a result of known and unknown risk factors and
uncertainties affecting HLS, including risks relating to the
specialty pharmaceutical industry, risks related to the regulatory
approval process, economic factors and many other factors beyond
the control of HLS. Forward-looking statements and information by
their nature are based on assumptions and involve known and unknown
risks, uncertainties and other factors which may cause HLS's actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking statement
or information. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. A
discussion of the material risks and assumptions associated with
this release can be found in the Company's Annual Information Form
dated March 13, 2024, and
Management's Discussion and Analysis dated May 8, 2024, both of which have been filed on
SEDAR and can be accessed at www.sedarplus.ca. Accordingly, readers
should not place undue reliance on any forward-looking statements
or information. Except as required by applicable securities laws,
forward-looking statements speak only as of the date on which they
are made and HLS undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise.
SOURCE HLS Therapeutics Inc.
